title: The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.
abstract: Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8(+) T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8(+) cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.
authors.affiliation: Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, USA. pavelko.kevin@mayo.edu
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Pavelko
authors.forename: Michael P
authors.initials: MP
authors.lastname: Bell
authors.forename: Lavakumar
authors.initials: L
authors.lastname: Karyampudi
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Hansen
authors.forename: Kathleen S
authors.initials: KS
authors.lastname: Allen
authors.forename: Keith L
authors.initials: KL
authors.lastname: Knutson
authors.forename: Larry R
authors.initials: LR
authors.lastname: Pease
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000941:Antigens / Q000276:immunology*; D001483:Base Sequence; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D018188:Cardiovirus Infections / Q000276:immunology / Q000401:mortality / Q000821:virology; D045744:Cell Line, Tumor; D000939:Epitopes / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000276:immunology; D051379:Mice; D008969:Molecular Sequence Data; D016254:Mutagenesis, Insertional; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D017945:Theilovirus / Q000235:genetics / Q000276:immunology*; D047368:Tumor Burden / Q000187:drug effects; D014613:Vaccines, Attenuated; D014764:Viral Proteins / Q000737:chemistry / Q000276:immunology
chemical_list: D000941:Antigens; D019496:Cancer Vaccines; D000939:Epitopes; D007370:Interferon Type I; D018719:Erb-b2 Receptor Tyrosine Kinases; D014613:Vaccines, Attenuated; D014764:Viral Proteins